Novo Nordisk's 1st-qtr sales increased by 27%

4 May 2023

Danish diabetes care giant Novo Nordisk’s (NOV: N) shares were down 4.8% at 1,069.40 kroner this morning, despite the company reporting first-quarter 2023 financials, showing that net sales increased 27% (+25% at constant currencies) to 53,367 million kroner ($7.91 billion).

Operating profit increased by 31% in Danish kroner and by 28% at CER to 25.0 billion kroner. Net profit was up 30% at 19,814 million kroner, with earnings per share (EPS) rising 41% to 8.78 kroner.

Sales in North America Operations increased by 47% in kroner (41% at CER). Wholesaler inventory movements in the US positively impacted sales growth. Sales in International Operations increased by 9% in kroner (10% at CER).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK